Advertisement

Molecular Imaging and Biology

, Volume 19, Issue 2, pp 215–224 | Cite as

Patterns of Vasculature in Mouse Models of Lung Cancer Are Dependent on Location

  • Marta Vilalta
  • Nicholas P Hughes
  • Rie Von Eyben
  • Amato J. Giaccia
  • Edward E. GravesEmail author
Research Article

Abstract

Purpose

Preclinical studies of hypoxia are generally done using ectopic xenograft tumors, which behave differently from human tumors. Our previous findings have shown that subcutaneously implanted lung tumors exhibit more hypoxia than their orthotopic implanted or spontaneous K-ras-induced counterparts. We hypothesize that differences in hypoxia are due to site-specific differences in vascularity and perfusion.

Procedures

To compare the presence and functionality of vessels in these tumor models, we studied vascular perfusion in vivo in real time.

Results

Orthotopically implanted and spontaneous K-ras-induced lung tumors showed elevated perfusion, demonstrating vasculature functionality. Little contrast agent uptake was observed within the subcutaneously implanted tumors, indicating vascular dysfunction. These findings were corroborated at the microscopic level with Hoechst 33342 and Meca-32 staining.

Conclusions

From these observations, we concluded that differences in hypoxia in experimental models is related to vessel perfusion. Thus, appropriate selection of preclinical lung tumor models is essential for the study of hypoxia, angiogenesis and therapies targeting these phenomena.

Key words

Preclinical models of cancer Xenograft models Non-invasive imaging in animal models Tumor microenvironment Vasculature 

Notes

Acknowledgments

We acknowledge Dr. Alejandro Sweet-Cordero for the donation of the spontaneous lung cancer mouse model and the assistance of Leanne Sayles with the mouse model. The funding for this study was provided by NCI R01 CA131199, NCI P01 CA067166, and Agència de Gestió d’Ajuts Universitaris i de Recerca, Generalitat de Catalunya.

Compliance with Ethical Standards

All animal experiments were done according to a protocol approved by the Institutional Animal Care and Use Committee.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62CrossRefPubMedGoogle Scholar
  2. 2.
    McDonald DM, Foss AJ (2000) Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev 19:109–120CrossRefPubMedGoogle Scholar
  3. 3.
    Morikawa S, Baluk P, Kaidoh T et al (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160:985–1000CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hashizume H, Baluk P, Morikawa S et al (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363–1380CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257CrossRefPubMedGoogle Scholar
  6. 6.
    Lunt SJ, Kalliomaki TM, Brown A et al (2008) Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours. BMC Cancer 8:2CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Moeller BJ, Richardson RA, Dewhirst MW (2007) Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 26:241–248CrossRefPubMedGoogle Scholar
  8. 8.
    Moding EJ, Kastan MB, Kirsch DG (2013) Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov 12:526–542CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845CrossRefPubMedGoogle Scholar
  10. 10.
    Marti HJ, Bernaudin M, Bellail A et al (2000) Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol 156:965–976CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Moeller BJ, Cao Y, Vujaskovic Z et al (2004) The relationship between hypoxia and angiogenesis. Semin Radiat Oncol 14:215–221CrossRefPubMedGoogle Scholar
  12. 12.
    Young SD, Marshall RS, Hill RP (1988) Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci U S A 85:9533–9537CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Brown JM (1999) The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59:5863–5870PubMedGoogle Scholar
  14. 14.
    Killion JJ, Radinsky R, Fidler IJ (1998) Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 17:279–284CrossRefPubMedGoogle Scholar
  15. 15.
    Hobbs SK, Monsky WL, Yuan F et al (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 95:4607–4612CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Fukumura D, Yuan F, Monsky WL et al (1997) Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol 151:679–688PubMedPubMedCentralGoogle Scholar
  17. 17.
    Ho KS, Poon PC, Owen SC, Shoichet MS (2012) Blood vessel hyperpermeability and pathophysiology in human tumour xenograft models of breast cancer: a comparison of ectopic and orthotopic tumours. BMC Cancer 12:579CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Waters DJ, Janovitz EB, Chan TC (1995) Spontaneous metastasis of PC-3 cells in athymic mice after implantation in orthotopic or ectopic microenvironments. Prostate 26:227–234CrossRefPubMedGoogle Scholar
  19. 19.
    Glinskii AB, Smith BA, Jiang P et al (2003) Viable circulating metastatic cells produced in orthotopic but not ectopic prostate cancer models. Cancer Res 63:4239–4243PubMedGoogle Scholar
  20. 20.
    Graves EE, Vilalta M, Cecic IK et al (2010) Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res 16:4843–4852CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Maity A, Koumenis C (2010) Location, location, location-makes all the difference for hypoxia in lung tumors. Clin Cancer Res 16:4685–4687CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    McDonald DM, Baluk P (2002) Significance of blood vessel leakiness in cancer. Cancer Res 62:5381–5385PubMedGoogle Scholar
  23. 23.
    Jackson A, O’Connor JP, Parker GJ, Jayson GC (2007) Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13:3449–3459CrossRefPubMedGoogle Scholar
  24. 24.
    Jackson EL, Willis N, Mercer K et al (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15:3243–3248CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Maatta AM, Makinen K, Ketola A et al (2008) Replication competent Semliki Forest virus prolongs survival in experimental lung cancer. Int J Cancer 123:1704–1711CrossRefPubMedGoogle Scholar
  26. 26.
    Graves EE, Quon A, Loo BW Jr (2007) RT_Image: an open-source tool for investigating PET in radiation oncology. Technol Cancer Res Treat 6:111–121CrossRefPubMedGoogle Scholar
  27. 27.
    Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232CrossRefPubMedGoogle Scholar
  28. 28.
    Nolan-Stevaux O, Truitt MC, Pahler JC et al (2010) Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes. Genes Cancer 1:125–141CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Jung J (2014) Human tumor xenograft models for preclinical assessment of anticancer drug development. Toxicol Res 30:1–5CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Field SB, Needham S, Burney IA et al (1991) Differences in vascular response between primary and transplanted tumours. Br J Cancer 63:723–726CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505–515CrossRefPubMedGoogle Scholar
  32. 32.
    Frese KK, Tuveson DA (2007) Maximizing mouse cancer models. Nat Rev Cancer 7:645–658CrossRefPubMedGoogle Scholar
  33. 33.
    Singh M, Murriel CL, Johnson L (2012) Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res 72:2695–2700CrossRefPubMedGoogle Scholar
  34. 34.
    Kerbel RS (2003) Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2:S134–S139PubMedGoogle Scholar
  35. 35.
    Dutt A, Wong KK (2006) Mouse models of lung cancer. Clin Cancer Res 12:4396s–4402sCrossRefPubMedGoogle Scholar
  36. 36.
    Olive KP, Jacobetz MA, Davidson CJ et al (2009) Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457–1461CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Downey CM, Aghaei M, Schwendener RA, Jirik FR (2014) DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2′3′-cGAMP, induces M2 macrophage repolarization. PLoS One 9:e99988CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Cai KX, Tse LY, Leung C et al (2008) Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin. Clin Cancer Res 14:939–949CrossRefPubMedGoogle Scholar
  39. 39.
    Benjamin LE, Golijanin D, Itin A et al (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159–165CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM (1988) Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133:95–109PubMedPubMedCentralGoogle Scholar
  41. 41.
    Dreher MR, Liu W, Michelich CR et al (2006) Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 98:335–344CrossRefPubMedGoogle Scholar
  42. 42.
    Shuhendler AJ, Prasad P, Cai P et al (2013) Matrigel alters the pathophysiology of orthotopic human breast adenocarcinoma xenografts with implications for nanomedicine evaluation. Nanomedicine 9:795–805PubMedGoogle Scholar
  43. 43.
    Chen B, Pogue BW, Zhou X et al (2005) Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin Cancer Res 11:720–727PubMedGoogle Scholar

Copyright information

© World Molecular Imaging Society 2016

Authors and Affiliations

  • Marta Vilalta
    • 1
  • Nicholas P Hughes
    • 1
  • Rie Von Eyben
    • 1
  • Amato J. Giaccia
    • 1
  • Edward E. Graves
    • 1
    Email author
  1. 1.Department of Radiation Oncology, Molecular Imaging Program at Stanford and Bio-X ProgramStanford UniversityStanfordUSA

Personalised recommendations